Thrombopoietin-Janus kinase 2-Signal transducer and activator of transcription 5 signaling pathway (TPO-JAK2-STAT5)

The Thrombopoietin-Janus kinase 2-Signal transducer and activator of transcription 5 (TPO-JAK2-STAT5) signaling pathway is a critical hematopoietic axis that regulates the production of platelets and the maintenance of hematopoietic stem cells [1, 5]. This signaling cascade is initiated by the binding of the hormone thrombopoietin (TPO) to its cognate receptor, MPL (the myeloproliferative leukemia protein), which triggers receptor dimerization and the activation of the associated Janus kinase 2 (JAK2) [1, 6]. Activated JAK2 then phosphorylates the cytoplasmic tail of MPL and recruits Signal Transducer and Activator of Transcription 5 (STAT5), which is subsequently phosphorylated, dimerizes, and translocates to the nucleus to initiate the transcription of genes involved in cell survival, proliferation, and megakaryocyte differentiation [2, 6]. Dysregulation of this pathway, often through gain-of-function mutations in JAK2 (e.g., V617F), MPL, or Calreticulin (CALR), is a hallmark of myeloproliferative neoplasms (MPNs) such as polycythemia vera and essential thrombocythemia [8, 9]. Therapeutic strategies targeting this axis include JAK2 inhibitors, which reduce pathological signaling in MPNs, and TPO receptor agonists, which are used to treat thrombocytopenia by stimulating the pathway [3, 5]. Monitoring the pathway often involves assessing the presence of driver mutations or the levels of phosphorylated STAT5 as biomarkers of disease activity and treatment response [7, 9].

Other names

TPO/MPL/JAK2/STAT5 pathwayThrombopoietin signaling pathwayMPL-JAK2-STAT5 axisTPO-JAK-STAT signaling

Inhibition of Janus kinase 2 activity, agonism of the thrombopoietin receptor, and subsequent modulation of STAT5 phosphorylation and gene transcription.